JENNIFER JABLONSKI: Open Payments
NPI 1336603976 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,184 in 39 payments from 11 companies in 2025. Trend: 2023 $428 · 2024 $489 · 2025 $1,184
Food & beverage: $1,184
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 18 | $752 |
| ABBVIE INC. | 4 | $75 |
| Insmed, Inc. | 4 | $73 |
| Astellas Pharma US Inc | 3 | $67 |
| Theratechnologies Inc. | 2 | $47 |
| Grifols USA, LLC | 2 | $47 |
| Paratek Pharmaceuticals, Inc. | 2 | $31 |
| Gilead Sciences, Inc. | 1 | $28 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Merck Sharp & Dohme LLC | 1 | $18 |
Products named: CABENUVA, DOVATO, Arikayce, Cresemba, EGRIFTA, Gamunex-C, DALVANCE, TEFLARO.
Industry payments across TX — which companies pay providers there.
